Less Is More: Cost-Effective Psoriasis Management via Disease-Driven Dosing of IL-17/IL-23 Inhibitors
Dermatology Practical & Conceptual · 31.07.2026 · 16 (3) · 6747
DOI: 10.5826/dpc.1603a6747 ↗Kurz gefasst
Fachartikel in der Zeitschrift Dermatology Practical & Conceptual, online erschienen am 31.07.2026. Verfasst von Edoardo Cammarata und 20 weiteren Autor:innen. Beteiligte Einrichtung: SCDU Dermatologia, AOU Maggiore della Carità, Novara, Italy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Introduction
Chronic plaque psoriasis is commonly treated with IL-17 and IL-23 inhibitors, which are highly effective but associated with substantial costs. Because many patients achieve long-term disease control, fixed-dose regimens may result in overtreatment.
Objectives
This study assessed the economic impact of disease-activity-guided dose reduction (DR) strategies using secukinumab, brodalumab, guselkumab, and risankizumab in adults with stable plaque psoriasis.
Methods
This cost analysis was based on data from the PSORED trial, a multicenter prospective open-label study conducted in Piedmont, Italy (2023–2025). Patients with stable disease (PASI ≤3, DLQI ≤3 for ≥9 months) underwent DR trough a 1.5x extension of maintenance dosing intervals. Costs under DR and standard dosing (SD) were compared over 52 weeks using Italian tariff data and real-world treatment patterns.
Results
Among 156 enrolled patients, 39 discontinued DR, 38 returned to standard dosing, and one switched therapy. DR reduced biologics consumption without increasing follow-up requirements, yielding a 26% decrease in total costs and an average annual saving of €7,303.57 per patient.
Conclusions
DR was both clinically effective and cost-saving, maintaining disease control without major safety concerns. These findings support the implementation of DR strategies in routine clinical practice to enhance long-term sustainability while preserving therapeutic efficacy.
Autor:innen und Institutionen
- SCDU Dermatologia, AOU Maggiore della Carità, Novara, Italy.
- Hospital Pharmacy, AOU Maggiore della Carità, Novara, Italy.
- Dermatologic Clinic, Department of Clinical Medicine, University of Turin, Turin, Italy.
- SSD Dermatologia, AO Santa Croce e Carle Hospital, Cuneo, Italy.
- SS Dermatologia, AOU SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.
- UO Dermatologia, Ospedale Koelliker, Torino, Italy.
Zitieren
APA
Cammarata, E., Airoldi, C., Colombo, J., Ucciero, A., Mastorino, L., Arese, V., Burzi, L., Castelli, F., Chiarpenello, M., Graziola, F., Leporati, C., Ortoncelli, M., Pella, P., Pertusi, G., Pisterna, A., Quaglino, P., Ribero, S., Rossotto, G., Tiberio, R., …, & Savoia, P. (2026). Less Is More: Cost-Effective Psoriasis Management via Disease-Driven Dosing of IL-17/IL-23 Inhibitors. Dermatology Practical & Conceptual, 16(3), 6747. https://doi.org/10.5826/dpc.1603a6747
Vancouver
Cammarata E, Airoldi C, Colombo J, Ucciero A, Mastorino L, Arese V, et al. Less Is More: Cost-Effective Psoriasis Management via Disease-Driven Dosing of IL-17/IL-23 Inhibitors. Dermatology Practical & Conceptual. 2026;16(3):6747. doi:10.5826/dpc.1603a6747
BibTeX
@article{Cammarata2026,
author = {Cammarata, Edoardo and Airoldi, Chiara and Colombo, Jacopo and Ucciero, Andrealuna and Mastorino, Luca and Arese, Veronica and Burzi, Lorenza and Castelli, Franco and Chiarpenello, Massimo and Graziola, Francesca and Leporati, Claudia and Ortoncelli, Michela and Pella, Paolo and Pertusi, Ginevra and Pisterna, Alessia and Quaglino, Pietro and Ribero, Simone and Rossotto, Gianluca and Tiberio, Rossana and Dapavo, Paolo and Savoia, Paola},
title = {Less Is More: Cost-Effective Psoriasis Management via Disease-Driven Dosing of IL-17/IL-23 Inhibitors},
journal = {Dermatology Practical & Conceptual},
year = {2026},
volume = {16},
number = {3},
pages = {6747},
doi = {10.5826/dpc.1603a6747}
}
EUVIMED